Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FHTX Foghorn Therapeutics	$6.13 +0.5%	$4.67	$2.94 ▼ $10.25	$341.69M	3.05	142,667 shs	12,220 shs
GOSS Gossamer Bio	$1.78 +3.8%	$1.26	$0.66 ▼ $1.89	$403.46M	1.86	1.46 million shs	1.39 million shs
RNAC Cartesian Therapeutics	$12.38 -1.2%	$10.63	$8.46 ▼ $26.50	$321.13M	0.36	97,940 shs	14,825 shs
SRZN Surrozen	$8.45 -0.6%	$8.50	$5.90 ▼ $18.17	$72.33M	0.59	21,991 shs	1,496 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FHTX Foghorn Therapeutics	+3.74%	+12.96%	+27.35%	+60.53%	-4.24%
GOSS Gossamer Bio	+3.01%	+25.74%	+37.90%	+103.57%	+56.88%
RNAC Cartesian Therapeutics	-5.58%	-7.46%	+27.99%	+19.33%	-31.98%
SRZN Surrozen	+1.19%	-0.82%	-7.81%	-12.82%	-9.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FHTX Foghorn Therapeutics	2.113 of 5 stars	3.6	0.0	0.0	3.3	1.7	0.6
GOSS Gossamer Bio	3.7839 of 5 stars	3.5	1.0	4.7	2.6	1.7	0.0
RNAC Cartesian Therapeutics	2.2634 of 5 stars	3.4	1.0	0.0	2.8	3.3	0.0
SRZN Surrozen	2.7883 of 5 stars	3.5	2.0	0.0	3.3	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	97.80% Upside
GOSS Gossamer Bio	3.00	Buy	$8.25	364.79% Upside
RNAC Cartesian Therapeutics	2.83	Moderate Buy	$40.00	223.23% Upside
SRZN Surrozen	3.00	Buy	$38.50	355.62% Upside

Current Analyst Ratings Breakdown

Latest SRZN, RNAC, FHTX, and GOSS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
7/9/2025	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
5/8/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$41.00 ➝ $40.00
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
4/30/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/23/2025	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FHTX Foghorn Therapeutics	$22.60M	15.12	N/A	N/A	($0.82) per share	-7.48
GOSS Gossamer Bio	$114.70M	3.52	N/A	N/A	$0.13 per share	13.65
RNAC Cartesian Therapeutics	$38.91M	8.25	N/A	N/A	($0.27) per share	-45.83
SRZN Surrozen	$10.65M	6.79	N/A	N/A	($6.55) per share	-1.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	N/A	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-41.12%	-128.98%	-15.52%	8/11/2025 (Estimated)
RNAC Cartesian Therapeutics	-$77.42M	-$52.83	N/A	N/A	N/A	N/A	N/A	-7.01%	8/6/2025 (Estimated)
SRZN Surrozen	-$63.56M	-$24.96	N/A	N/A	N/A	N/A	-842.90%	-71.32%	8/11/2025 (Estimated)

Latest SRZN, RNAC, FHTX, and GOSS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FHTX Foghorn Therapeutics	-$0.32	N/A	N/A	N/A	N/A	N/A
8/14/2025	N/A	RNAC Cartesian Therapeutics	-$0.77	N/A	N/A	N/A	$0.77 million	N/A
8/11/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	N/A	N/A	N/A	$4.12 million	N/A
8/11/2025	Q2 2025	SRZN Surrozen	-$1.23	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/9/2025	Q1 2025	SRZN Surrozen	-$1.09	-$3.13	-$2.04	-$7.43	N/A	$0.98 million
5/8/2025	Q1 2025	RNAC Cartesian Therapeutics	-$0.61	-$0.68	-$0.07	-$0.68	$0.69 million	$1.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FHTX Foghorn Therapeutics	N/A	3.16	3.16
GOSS Gossamer Bio	6.70	5.71	5.71
RNAC Cartesian Therapeutics	N/A	12.34	12.34
SRZN Surrozen	N/A	10.02	10.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FHTX Foghorn Therapeutics	61.55%
GOSS Gossamer Bio	81.23%
RNAC Cartesian Therapeutics	86.95%
SRZN Surrozen	66.57%

Insider Ownership

Company	Insider Ownership
FHTX Foghorn Therapeutics	7.58%
GOSS Gossamer Bio	6.70%
RNAC Cartesian Therapeutics	60.30%
SRZN Surrozen	45.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable
RNAC Cartesian Therapeutics	64	25.95 million	10.30 million	Optionable
SRZN Surrozen	80	8.56 million	4.69 million	Not Optionable

SRZN, RNAC, FHTX, and GOSS Headlines

Recent News About These Companies

Surrozen (NASDAQ:SRZN) Stock Price Down 0.1% - Here's Why

July 17 at 4:13 AM | marketbeat.com

We Think Surrozen (NASDAQ:SRZN) Can Afford To Drive Business Growth

July 1, 2025 | finance.yahoo.com

Surrozen (NASDAQ:SRZN) Shares Down 1.4% - What's Next?

June 25, 2025 | marketbeat.com

Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround

May 16, 2025 | zacks.com

Surrozen secures patent for tissue repair technology

May 15, 2025 | investing.com

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

May 14, 2025 | globenewswire.com

Surrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 10, 2025 | finanznachrichten.de

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025 | globenewswire.com

Surrozen files to sell 5.21M shares of common stock for holders

April 25, 2025 | markets.businessinsider.com

Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year

April 2, 2025 | markets.businessinsider.com

Insiders Are Loving These 5 Tech and Biotech Stocks

April 2, 2025 | 247wallst.com

Surrozen Focuses on Ophthalmology Amid Financial Challenges

April 1, 2025 | tipranks.com

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

March 31, 2025 | globenewswire.com

Surrozen, Inc. (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Purchases 1,034,482 Shares

March 29, 2025 | insidertrades.com

Surrozen to focus Wnt expertise, technologies on ophthalmology programs

March 27, 2025 | markets.businessinsider.com

Surrozen to discontinue development of SZN-043 in alcohol associated hepatitis

March 26, 2025 | markets.businessinsider.com

Surrozen, Inc. Prioritizes Ophthalmology Pipeline with $175 Million Financing and Discontinues SZN-043 Development

March 24, 2025 | quiverquant.comQ

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

March 24, 2025 | globenewswire.com

Surrozen (NASDAQ:SRZN) Stock Quotes, Forecast and News Summary

January 30, 2025 | benzinga.com

HC Wainwright & Co. Initiates Coverage of Surrozen (SRZN) with Buy Recommendation

January 30, 2025 | msn.com

H.C. Wainwright sets $32 target on Surrozen stock with Buy rating

January 30, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN, RNAC, FHTX, and GOSS Company Descriptions

Foghorn Therapeutics NASDAQ:FHTX

$6.13 +0.03 (+0.49%)

As of 10:28 AM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Gossamer Bio NASDAQ:GOSS

$1.78 +0.07 (+3.80%)

As of 10:29 AM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Cartesian Therapeutics NASDAQ:RNAC

$12.38 -0.16 (-1.24%)

As of 10:28 AM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Surrozen NASDAQ:SRZN

$8.45 -0.05 (-0.59%)

As of 09:42 AM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time